Effective components of Shengxian Decoction and its mechanism of action in treating chronic heart failure based on UHPLC-Q-TOF-MS integrated with network pharmacology.
10.19540/j.cnki.cjcmm.20200915.201
- Author:
Ying MA
1
;
Bo-Long WANG
2
;
Liang WANG
3
;
Cui-Yun HUANG
4
;
Mei SUN
3
;
Guang-Yang JIAO
4
;
Feng ZHANG
4
;
Wan-Sheng CHEN
5
Author Information
1. Department of Pharmacy, Changzheng Hospital, Second Military Medical University Shanghai 200003, China Chemistry and Biological Engineering College, Yichun University Yichun 336000, China.
2. Chemistry and Biological Engineering College, Yichun University Yichun 336000, China.
3. Institute of Chinese Materia Madica, Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
4. Department of Pharmacy, Changzheng Hospital, Second Military Medical University Shanghai 200003, China.
5. Department of Pharmacy, Changzheng Hospital, Second Military Medical University Shanghai 200003, China Institute of Chinese Materia Madica, Shanghai University of Traditional Chinese Medicine Shanghai 201203, China.
- Publication Type:Journal Article
- Keywords:
Shengxian Decoction;
UHPLC-Q-TOF-MS;
chronic heart failure;
network pharmacology;
serum pharmacochemistry;
signaling pathways
- MeSH:
Animals;
Chromatography, High Pressure Liquid;
Drugs, Chinese Herbal;
Heart Failure/genetics*;
Rats;
Rhizome;
Signal Transduction
- From:
China Journal of Chinese Materia Medica
2021;46(10):2489-2500
- CountryChina
- Language:Chinese
-
Abstract:
This study aimed to elucidate the effective components of Shengxian Decoction and its mechanism of action in treating chronic heart failure. Firstly, UHPLC-Q-TOF-MS was established to identify the main chemical constituents in the rat serum after intragastric administration with Shengxian Decoction. Secondly, the absorbed components in serum were then used for the network pharmacology analysis to infer the mechanism and effective components. Targets for constituents in serum were predicted at TCMSP and Swiss-TargetPrediction database. An association network map was drawn by network visualization software Cytoscape 3.6.1. Finally, GO enrichment analysis and KEGG pathway enrichment analysis were carried out for the core target genes. By UHPLC-Q-TOF-MS, 18 prototype compounds were definitely identified, including five compounds from Astragali Radix, four compounds from Anemarrhenae Rhizoma, four compounds from Bupleuri Radix, four compounds from Cimicifugae Rhizoma, and one compound from Platycodonis Radix. Those components of Shengxian Decoction were closely associated with 13 key protein targets, including inflammatory factors, like IL6, IL1 B, TNF, PTGS2, IL10; redox enzymes CAT, HMOX1, and MPO; cardiovascular targets, like VEGFA, NOS3, and NOS2; and transmememial proteins CAV1 and INS. Network pharmacology analysis showed that the 18 compounds could be responsible for the treatment of chronic heart failure by regulating HIF-1 signaling pathways, PI3 K-Akt signaling pathways, cGMP-PKG signaling pathways, cAMP signaling pathways and TNF signaling pathways. This study provided a scientific basis for mechanism and effective ingredients of Shengxian Decoction.
